Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion type Assertion NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_head.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion description "[Furthermore, anti-IL-6R mAb could provide novel therapy for Castleman's disease and MR16-1 should be a useful tool to estimate therapeutic potential of IL-6 antagonists in a variety of murine models for human disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_provenance.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion evidence source_evidence_literature NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_provenance.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion SIO_000772 12633573 NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_provenance.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion wasDerivedFrom befree-20140225 NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_provenance.
- NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_assertion wasGeneratedBy ECO_0000203 NP544614.RAEL-epEJeyHuTTeSEWwuOt2ODU3kvybnp5hyP1g2xk-4130_provenance.